## SEC Form 4

 $\Box$ 

# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

1. Name and Addres	s of Reporting Person	* I	2. Issuer Name <b>and</b> Ticker or Trading Symbol BICYCLE THERAPEUTICS plc [ BCYC ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
	AIL			X	Director	10% Owner		
	(First)	-	3. Date of Earliest Transaction (Month/Day/Year) 05/28/2019		Officer (give title below)	Other (specify below)		
B900, BABRAHAM RESEARCH CAMPUS			4. If Amendment, Date of Original Filed (Month/Day/Year)	Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Ap Line)				
(Street) CAMBRIDGE	X0	CB22 3AT		X	Form filed by One Rep Form filed by More tha Person	0		
(City)	(State)	(Zip)						

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount (A) or (D)		Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Ordinary Shares	05/28/2019		С		874,709	A	(1)	874,709	I	By SV Life Sciences Fund V, L.P. <sup>(2)</sup>
Ordinary Shares	05/28/2019		С		623,196	A	(1)	1,497,905	I	By SV Life Sciences Fund V, L.P. <sup>(2)</sup>
Ordinary Shares	05/28/2019		С		18,485	A	(1)	18,485	I	By SV Life Sciences Fund V Strategic Partners. L.P. <sup>(3)</sup>
Ordinary Shares	05/28/2019		С		13,169	A	(1)	31,654	I	By SV Life Sciences Fund V Strategic Partners. L.P. <sup>(3)</sup>
Ordinary Shares	05/28/2019		Р		377,732	A	\$14	1,875,637	I	By SV Life Sciences Fund V, L.P. <sup>(2)</sup>
Ordinary Shares	05/28/2019		Р		7,983	A	\$14	39,637	I	By SV Life Sciences Fund V Strategic Partners. L.P. <sup>(3)</sup>

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	 3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
								(Instr. 4)		

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	<del>3. Transaction Date</del> (Month/Day/Year)	Table II - Deri (e.g. <del>3A. Deemed</del> Execution Date, if any (Month/Day/Year)	Vative Securities Acq puts, calls, warrants Code V (A) (B) 4. 5. Number of Transaction Code (Instr. 8) Scurities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			arrants (D) umber of vative urities uired (A) isposed D) (Instr.	uired, Dis "Daptions, Exercisable 6. Date Exerc Expiration Da (Month/Day/h	ble secunities)		B. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Data			Amount or Number				
Series A				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	of Shares				By SV Life Sciences
Preferred Shares	(1)	05/28/2019		С			874,709	(1)	(1)	-Ordinary- Shares	874,709	(1)	0	I	Fund V, L.P. <sup>(2)</sup>
Series B1 Preferred Shares	(1)	05/28/2019		С			623,196	(1)	(1)	Ordinary Shares	623,196	(1)	0	I	By SV Life Sciences Fund V, L.P. <sup>(2)</sup>
Series A Preferred Shares	(1)	05/28/2019		С			18,485	(1)	(1)	Ordinary Shares	18,485	(1)	0	I	By SV Life Sciences Fund V Strategic Partners. L.P. <sup>(3)</sup>
Series B1 Preferred Shares	(1)	05/28/2019		С			13,169	(1)	(1)	Ordinary Shares	13,169	(1)	0	I	By SV Life Sciences Fund V Strategic Partners. L.P. <sup>(3)</sup>

#### Explanation of Responses:

1. Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.

2. These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and the individual scomprising the securities of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.

3. These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein

/s/ Lee Kalowski, as Attorneyin-Fact 05/30/2019

Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.